Atria is a Dividend King with an impressive track record for dividend growth. Eli Lilly has been raising its dividend at a more impressive pace than Altria in recent years. Altria has an ...

Eli Lilly and Company is the world's most valuable Pharma thanks to tirzepatide, a groundbreaking GLP-1 weight-loss and Type 2 Diabetes drug, marketed and sold as Zepbound / Mounjaro. Hims & Hers ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim Cramer discusses. On Wednesday, Jim Cramer, the host of Mad Money ...

Eli Lilly is expected to release data on its weight loss pill as early as April. Positive trial data could suggest the drug's approval may be on the horizon. The company already has a highly ...

Eli Lilly (NYSE:LLY) on Tuesday will file lawsuits against two companies that the drug giant is accusing of mass compounding its blockbuster GLP-1/GIP receptor agonist tirzepatide. Tirzepatide is ...

Eli Lilly is suing two pharmacies for compounding Zepbound and Mounjaro, claiming the companies are skirting the Food and Drug Administration's ban on the practice and luring people away from ...

Eli Lilly (LLY) is targeting additional drug compounders and telehealth companies that make copycat versions of its weight loss drug, with plans to file two lawsuits and send about 50 cease-and ...

Shares of Eli Lilly fall 2.9%, to $717.02, in after-hours trading. American depository receipts of Novo Nordisk slide 1.4%, to $61.68, and shares of Hims & Hers edge 1.2% lower, to $25.68.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... He took over as CEO of his family’s medical device company in 2011 following his father’s death.

This is roughly $800 more than the list price Eli Lilly & Co. charges for its drug, and includes a Hims membership, unlimited consultations with a provider and treatment support, the spokesperson ...